Kondo Yamanaka
Mucosal vaccination presents a promising avenue for enhancing immune responses against pathogens, particularly those that enter the body through mucosal surfaces. However, the development of effective mucosal vaccines faces numerous challenges, including antigen stability, delivery efficiency and immune stimulation. In recent years, Polymeric Caffeic Acid (PCA) has emerged as a novel antigen carrier with remarkable potential for mucosal vaccine applications. PCA, derived from natural sources, offers several advantages, including biocompatibility, biodegradability and immunomodulatory properties. This article provides an overview of the recent advances in utilizing PCA as an antigen carrier for mucosal vaccines, highlighting its unique properties, formulation strategies and potential applications in combating infectious diseases.
PDFShare this article
Pharmaceutical Regulatory Affairs: Open Access received 533 citations as per Google Scholar report
